This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Milan, InSilicoTrials has been innovating the healthcare sector for some years now, helping pharmaceuticalcompanies reduce the time and cost of drugdevelopment using modeling & simulation.
Create a pharmaceuticalcompany that leverages the best of what the U.S. and China have to offer toward discovering and developing new oncology therapeutics, while using the smallest drugdevelopment program possible to do so. Their desire?
Thomas Turi, chief scientific officer at Nexelis, tells us how a biomarker-led R&D approach is transforming drugdevelopment in disease areas like non-alcoholic steatohepatitis (NASH) and cancer, and provides best-practice tips for companies looking to harness this approach.
“But we are glad to see the situation for innovative drugs in Asian markets improving, especially in mainland China and South Korea, where policies, societies and regulations are actively promoting innovation. “At At the same time, lots of people with experience at multinational pharmaceuticalcompanies have chosen to return home.
Access to medicines attracts a great deal of interest from patients, clinicians, and the public and there have been significant advances in drugdevelopment in recent years which looks set to continue. How the combination treatment challenge impacts patients and how we are working together to solve it.
Pharma is embracing patient centricity in drugdevelopment. Replicate a drug’s EU market success in the US requires pharma to be fully aware of the ever-changing national and state requirements and regulations, says Two Labs’ Howard Miller. Navigating the patient maze – pharma’s evolving challenge.
This allows pharmaceuticalcompanies to maintain their brand voice and facilitates information sharing. Many aspiring medical writers falsely believe they should market their services only to pharmaceutical and medical device companies. All their claims are well-researched and supported by data.
Effective and accurate candidate molecule screening and optimization has become one of the primary challenges for pharmaceuticalcompanies. Through its range of services, Creative Biolabs, in particular, speeds up the overall drug discovery process through antibody drugdevelopment.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content